Biblio

22 Ergebnisse exportiert:
Autor Titel Typ [ Jahr(Asc)]
Filterkriterien: Anfangsbuchstabe Des Nachnamens is H  [Alle Filter deaktivieren]
2010
Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, u. a.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428PDF Icon Pipsa Saharinen et al., Genes & Development 2010 (1.2 MB)PDF Icon Pipsa Saharinen et al., Genes & Development 2010, supplement (9.15 MB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF Icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF Icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF Icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF Icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF Icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF Icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, u. a.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF Icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, u. a.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF Icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF Icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
2008
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, u. a.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF Icon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF Icon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, u. a.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF Icon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF Icon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, u. a.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF Icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, u. a.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF Icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
2005
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, u. a.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF Icon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, u. a.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF Icon Yulong He et al., Cancer Research 2005 (1.82 MB)
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, u. a.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF Icon Yulong He et al., Cancer Research 2005 (1.82 MB)
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, u. a.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF Icon Yulong He et al., Cancer Research 2005 (1.82 MB)